The two faces of transforming growth factor β in carcinogenesis
By A. Roberts, L. Wakefield. Proceedings of the National Academy of Sciences of the United States of America, 2003
732 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/a47c60ac75770b75e5e7de4384ae0d22a97eefcd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- R. Weinberg
- J. Massagué
- Jiri Zavadil
- Erwin P. Bottinger
- K. Polyak
- K. Miyazono
- A. Richardson
- Mahmut Yilmaz
In Oncology
- R. Weinberg
- J. Massagué
- K. Polyak
- Gerhard Christofori
- H. Ikushima
- A. Richardson
- K. Miyazono
- D. Hanahan
In Pathology and Forensic Medicine
Citations in the corpus
- EMT, the cytoskeleton, and cancer cell invasion (2009, background): “TGFβ usually acts as a cytostatic, tumor suppressing factor, but it promotes tumor progression and invasion, if the tumor cells overcome its cytostatic and apoptotic effects [126].”
- Molecular definition of breast tumor heterogeneity. (2007, background): “The TGF-b Pathway in Breast Cancer CD44+ Cells Due to the known importance of TGF-b signaling in regulating the pluripotency of human embryonic stem cells (James et al., 2005); its roles in differentiation, tumorigenesis, and metastasis (Moses and Serra, 1996; Muraoka-Cook et al., 2005; Roberts and”
- TGFβ signalling: a complex web in cancer progression (2010, background): “Future directions TGFβ can function as a tumour-suppressing or tumour-promoting factor in cancer progressio”
- TGFβ in Cancer (2008, background): “…are clustered in one family branch, and bone morphogenetic proteins (BMPs), anti-muellerian hormone (AMH, also known as MIS), and various growth and differentiation factors (GDFs) are grouped into the other branch (Derynck and Akhurst, 2007; Roberts and Wakefield, 2003; Shi and Massagué, 2003).”
- TGF-β and epithelial-to-mesenchymal transitions (2005, background): “…body of work established new roles for TGF-bs as important mediators of tumor progression, and in progression of chronic fibrotic disorders, in particular chronic kidney disease (reviewed in Border and Noble, 1994; Derynck et al., 2001; Bottinger and Bitzer, 2002; Roberts and Wakefield, 2003).”